8-K: AngioDynamics Reports Record FY26 Results, Med Tech Drives Growth

AngioDynamics announced record fiscal year 2026 results, driven by strong double-digit growth in its Med Tech segment, achieving full-year profitability and ending the year with a debt-free balance sheet.

Summary

• AngioDynamics reported record financial results for the fiscal fourth quarter and full year ended May 31, 2026.
• The company achieved its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA.
• Pro forma net sales for the fiscal year 2026 increased by 9.4% to $320.2 million, with Med Tech net sales up 18.4% to $150.0 million.
• GAAP gross margin for the full year was 54.6%, and the company ended the fiscal year with $53.9 million in cash and a debt-free balance sheet.
• Several clinical and regulatory milestones were achieved, including FDA IDE approvals for studies evaluating the AlphaReturn Blood Management System and the AngioVac System, and a Medicare coverage determination for NanoKnife IRE.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth in key segments, achievement of profitability metrics, and significant clinical/regulatory progress, although GAAP net loss persists.

Positives

• Record fiscal year 2026 net sales of $320.2 million, a 9.4% increase year-over-year.
• Strong Med Tech segment net sales growth of 18.4% to $150.0 million for the full year.
• Achieved positive adjusted EBITDA of $13.2 million for the full year 2026.
• Ended fiscal year 2026 with $53.9 million in cash and a debt-free balance sheet.
• Received FDA IDE approvals for the APEX-Return study (AlphaReturn) and the PAVE clinical study (AngioVac).
• Secured a local coverage determination from Palmetto GBA for NanoKnife IRE for qualifying Medicare patients in prostate and liver cancer, effective July 5, 2026.
• Auryon platform delivered its 20th consecutive quarter of double-digit growth.
• NanoKnife adoption accelerated following the effective date of the Category I CPT code for prostate.

Negatives

• Reported a GAAP net loss of $36.7 million for the full year 2026, compared to a net loss of $33.9 million in the prior year.
• Adjusted net loss for the full year 2026 was $10.0 million, a slight improvement from $10.2 million in the prior year.
• Med Device net sales saw a modest increase of 2.5% to $170.2 million for the full year.
• AngioVac sales declined 15.8% in the fourth quarter compared to the prior year, though it grew 2.1% for the full year.

Risks

• The scale and scope of the COVID-19 global pandemic.
• Ability to develop existing and new products.
• Technological advances and patents attained by competitors.
• Infringement of AngioDynamics technology or assertions that it infringes third-party technology.
• Ability to effectively compete against competitors with substantially greater resources.
• Future actions by the FDA or other regulatory agencies.
• Overall economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges.
• Results of pending or future clinical trials.

Future Outlook

For fiscal year 2027, AngioDynamics anticipates net sales between $336.0 million and $341.0 million, with Med Tech net sales expected to grow between 12% and 15%, while Med Device net sales are projected to be flat. Gross margin is expected to be between 54% and 55%. Adjusted EBITDA is projected to be in the range of $13.0 million to $16.0 million, and adjusted EPS is forecasted to be between ($0.29) and ($0.24). The company expects to generate positive cash flow from operations in FY27.

Management Comments

• "Our strong fourth quarter capped a year of consistent execution at AngioDynamics," said Jim Clemmer, President and Chief Executive Officer.
• "Full-year Med Tech growth of more than 18% reflects the continued progress of our strategic transformation, as our innovative platform technologies across cardiology and interventional oncology took share in large, fast-growing global markets."
• "We advanced our portfolio on multiple fronts during the year. We generated compelling two-year PRESERVE clinical data and secured a critical Medicare coverage pathway for NanoKnife in prostate and liver, while achieving key regulatory milestones across our Mechanical Thrombectomy portfolio."
• "As we look ahead to fiscal 2027, we remain focused on driving sustained growth led by our Med Tech segment."
• "With a differentiated technology portfolio, multiple growth catalysts ahead, and a debt-free balance sheet with positive cash generation, we are well-positioned to deliver continued value creation in fiscal 2027 and beyond."

Industry Context

StockSavvy.ai notes that AngioDynamics' performance highlights a strategic shift towards higher-margin, growth-oriented MedTech segments, aligning with broader industry trends of specialization and innovation in medical devices. The company's focus on interventional oncology and vascular solutions positions it within rapidly expanding markets.

Comparison to Industry Standards

• The Med Tech segment's 18.4% year-over-year growth for FY26 significantly outpaces the typical growth rates seen in the broader medical device industry, which often ranges from low to mid-single digits.
• The company's focus on specific niches like mechanical thrombectomy and irreversible electroporation (NanoKnife) allows for specialized growth, potentially exceeding benchmarks set by diversified medical device conglomerates.
• Achieving positive Adjusted EBITDA ($13.2 million for FY26) while investing in R&D and clinical trials demonstrates operational efficiency that may be superior to some peers facing margin pressures.
• The debt-free balance sheet is a strong indicator of financial health, providing flexibility that may not be common among competitors that carry significant debt loads.

Legal Proceedings

• The filing mentions 'results of on-going litigation' as a potential risk factor, but provides no specific details on current legal proceedings.

Stakeholder Impact

• Shareholders: Potential for increased value creation due to strong revenue growth, profitability, and a debt-free balance sheet.
• Employees: Continued focus on strategic initiatives and growth may lead to opportunities and stability.
• Customers: Access to innovative medical technologies for vascular restoration, cancer treatment, and improved patient quality of life.
• Creditors: The debt-free status of the company reduces financial risk for creditors.

Next Steps

• Continue to drive sustained growth led by the Med Tech segment.
• Focus on shifting the revenue mix towards higher-growth, higher-margin platforms.
• Execute on strategic initiatives and leverage differentiated technology portfolio.
• Advance clinical trials including AMBITION BTK, RECOVER-AV, APEX-Return, and PAVE.
• Expand the addressable market for NanoKnife IRE into benign prostatic hyperplasia (BPH) with the RELIEF study.

Key Dates

Recommendation

The company demonstrates strong execution and growth in its Med Tech segment, achieving profitability and a solid balance sheet. However, the persistent GAAP net loss and the inherent risks in the medical technology sector warrant a cautious 'hold' recommendation until sustained GAAP profitability is achieved and the full impact of ongoing clinical trials and market adoption is clearer.

Keywords

AngioDynamics, Medical Technology, Med Tech, Med Device, Financial Results, Revenue Growth, Adjusted EBITDA, NanoKnife